# AMARIN CORP PLC\UK (AMRN) · Edgar & Edgarette company card

> Amarin Corp Plc\Uk (AMRN) saw revenue fall 6.5% in FY2025 to $214 million, operating margin -23.5% against a -3.8% median for pharmaceutical preparations, equity 68.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 897448 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/AMRN) · [JSON](https://www.pops4.com/boards/company/AMRN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $214M |
| Revenue growth, 1 year | -6.5% |
| Revenue growth per year | -22.2% |
| Operating margin | -23.5% (prior year -40.2%) |
| Net margin | -18.2% |
| Operating cash flow | $7M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $135M |
| Long-term debt | — |
| Total assets | $671M |
| Total equity | $459M |
| Equity ÷ assets | 68.5% |
| Return on equity | -8.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.07 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: Weathered boat · two warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating loss: a margin of -23.5% in FY2025
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $213.6M (FY2025). Experience: revenue down 6.5% on the year, down 22.2% a year over 4 years; operating margin -23.5%, up from -40.2%. Soundness: equity 68.5% of assets, return on equity -8.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $147.9M and $232.3M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $132.0M to $261.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -23.5% against a -3.8% median; growth -6.5% against 13.7%.

Range logged 2026-11-01, receipt 2f74c86b5e8d73da, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-11-18 ([filing](https://www.sec.gov/Archives/edgar/data/897448/000119312526467256/0001193125-26-467256-index.htm))

## Recent filings

- 8-K · filed 2026-11-18 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/897448/000119312526467256/0001193125-26-467256-index.htm)
- 10-Q · filed 2026-10-28 · [filing](https://www.sec.gov/Archives/edgar/data/897448/000119312526435082/0001193125-26-435082-index.htm)
- 8-K · filed 2026-10-28 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/897448/000119312526435081/0001193125-26-435081-index.htm)
- 10-Q · filed 2026-07-29 · [filing](https://www.sec.gov/Archives/edgar/data/897448/000119312526323845/0001193125-26-323845-index.htm)
- 8-K · filed 2026-07-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/897448/000119312526323841/0001193125-26-323841-index.htm)
- 8-K · filed 2026-05-15 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/897448/000119312526224771/0001193125-26-224771-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000897448.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=897448

## Cite

POPS4, Edgar & Edgarette: AMARIN CORP PLC\UK (AMRN) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/AMRN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

